Open Access

Small RNAs in the peripheral blood discriminate metastasized from non-metastasized seminoma

  • Christian G Ruf1, 2Email author,
  • Daniela Dinger1,
  • Matthias Port2, 4,
  • Hans-Ulrich Schmelz2, 3,
  • Walter Wagner1,
  • Cord Matthies1,
  • Bertram Müller-Myhsok5,
  • Viktor Meineke2 and
  • Michael Abend2
Molecular Cancer201413:47

https://doi.org/10.1186/1476-4598-13-47

Received: 15 December 2013

Accepted: 24 February 2014

Published: 6 March 2014

Abstract

Background

We aimed to better discriminate metastasized (lymphogen/occult/both combined) from non-metastasized seminoma based on post-transcriptional changes examined in the peripheral blood.

Methods

Total RNAs including small RNAs were isolated from the peripheral blood of patients suffering from metastasized testicular tumours (lymphogen, n = 5, clinical stage IIb/c; occult, n = 5, clinical stage I) and non-metastasized patients (n = 5, clinical stage I). Small RNA next generation sequencing (SOLID, Life Technologies) was employed to examine post-transcriptional changes. We searched for small RNAs showing at least 50 reads and a significant ≥ 2-fold difference using peripheral blood small RNAs of non-metastasized tumours as the reference group. Candidate small RNAs were examined in univariate logistic regression analysis and combinations of two small RNAs were further examined using support vector machines.

Results

On average 1.3x107, 1.2x107 and 1.2x107 small RNA reads were detectable in non-metastasized, lymphogen and occult metastasized seminoma, respectively of which 73-76% remained after trimming. From these between 80-82% represented annotated reads and 7.2-7.8% (1.6-1.7x104) were annotated small RNA tags. Of them 137 small RNAs showed > 50 reads and a ≥ two-fold difference to the reference. In univariate analysis we detected 33-35 different small RNAs which significantly discriminated lymphogen/occult/combined metastasized from non-metastasized seminoma and among these different comparisons it were the same small RNAs in 44-79%. Many combinations of two of these small RNAs completely discriminated metastasized from non-metastasized seminoma irrespective of the metastasis subtype.

Conclusions

Metastasized (either lymphogen or occult) seminoma can be completely discriminated from non-metastasized seminoma with a combination of two small RNAs measured in the peripheral blood.

Keywords

Testis tumourGene expressionSmall RNAMicroRNAMetastasized seminomaNext generation sequencingRisk factorTumour markerBlood

Background

Testicular tumor, as the most common tumor in young men, is associated with a 5 year survival rate close to 100% in early stages. Pure seminoma are the most frequent histological subtype (55%) nowadays and more than 70% of patients present without visible metastasis at primary staging [1]. Gold standard for primary staging is computed tomography (CT) of the chest, abdomen and pelvis to detect metastases. In truly non-metastasized clinical stage I (cS I) patients are cured by orchidectomy alone, but despite modern staging and classification procedures up to 30% of cS I seminoma patients’ bear occult metastasis in primary staging and relapse after orchidectomy alone [2, 3]. Until today no reliable biological parameters exist and clinical parameter are showing a concordance of 65% only in differentiating occult metastasized stages from non-metastasized seminoma [4]. Identification of occult metastasized patients is one of the main goals to prevent toxicity (e.g. cardiovascular and kidney disease, secondary malignancies and decreased fertility) caused by unnecessary adjuvant treatment or diagnostic procedures (additional radiation exposure due to quarterly CT scans) during follow up [5].

Recently, other authors started to examine whether a certain set of micro RNAs (miRNA) might be suitable for discriminating between seminoma bearing patients and healthy persons [68]. Expression of miRNAs in testicular germ cell cancer is also known to be associated with the histologic subtype [7] as well as cisplatin resistance [9, 10]. Additionally miRNAs are known to be involved in different processes of metastatic spread in other tumours [11]. Among seminoma bearing patients circulating tumour cells are already detected in the peripheral blood [12]. We wondered whether changes in microRNA expression in the peripheral blood might be able to discriminate metastasized (either lymphogen, occult or a combination of both subtypes) from non-metastasized seminoma. We utilized an agnostic approach investigating the whole genome for any kind of small RNA species suitable to discriminate metastatic stage in seminoma employing next generation sequencing (NGS) on peripheral blood samples drawn at the time of the primary tumour’s diagnosis.

Results

Characteristics of seminoma groups

The average age at diagnosis was 39.1 (+/- 7.2) years for non-metastasized, higher (45.2 years, +/- 10.8) for lymphogen metastasized and lower (32.1 years, +/- 5.4) for occult metastasized seminoma. Primary tumor size was comparable between lymphogen and occult metastasized seminoma (37.8 mm and 38.6 mm, respectively), but smaller (23.8 mm) in non-metastasized seminoma (Table 1).
Table 1

Characteristics of patients, their biopsies and RNA isolates

#

Metastasis detection at time of primary tumor’s diagnosis

Age at diagnosis (years)

Tumor size (mm)

pL

pV

pT

Infiltration rete testis

Initial clinical stage

Total RNA (μg)

RIN

1

Non metastasized

38

14

0

0

1

n

cSI

7.6

7.8

2

50

22

0

0

1

n

cSI

8.6

8.3

3

31

19

1

0

1

n

cSI

6.4

7.0

4

42

45

0

0

1

y

cSI

3.9

8.0

5

35

19

0

0

1

y

cSI

8.2

7.6

Mean

 

39.1

23.8

     

6.9

7.7

stdev

 

7.2

12.2

     

1.9

0.5

1

Lymphogen metastasized

32

40

0

0

1

n

cSIIb

5.0

8.5

2

50

12

0

0

3

n

cSIIc

5.1

8.8

3

43

50

0

0

1

n

cSIIb

8.1

8.3

4

42

45

1

0

2

y

cSIIb

3.2

9.3

5

61

42

0

0

1

y

cSIIc

3.2

8.2

Mean

 

45.2

37.8

     

4.9

8.6

stdev

 

10.8

14.9

     

2.0

0.4

1

Occult metastasized

33

55

1

0

2

n

cSI

5.0

6.0

2

37

35

0

0

1

y

cSI

4.1

7.4

3

37

30

0

0

1

n

cSI

7.0

7.8

4

31

18

0

0

1

n

cSI

8.1

7.4

5

23

55

0

0

1

n

cSI

10.0

6.4

Mean

 

32.1

38.6

     

6.8

7.0

stdev

 

5.4

16.2

     

2.4

0.8

RNA isolation

Per 2.5 ml whole blood we isolated about the same amount (mean) of total RNA from seminoma patients without metastasis (7.7 μg, +/-1.9), lymphogen metastasis (4.9 μg, +/-2.0 μg) and occult metastasis (6.8 μg, +/-2.4, Table 1). The RNA integrity number (RIN) ranged between 7.0-8.6 per group. No DNA contamination could be detected in our samples.

Analysis of small RNA next generation sequencing results

The average total number of reads for lymphogen/occult metastasized and non-metastasized seminoma was 1.3x107, 1.2x107 and 1.2x107 and on average 73-76% remained for further analysis after trimming of the reads (Table 2). From these reads 80-84% appeared annotated reads with 7.2-7.8% (1.6-1.7x104) representing annotated small RNAs. Of them 137 small RNAs showed > 50 reads and a two-fold difference to the reference. In univariate analysis we identified 33/34 and 35 small RNA species which significantly discriminated lymphogen/occult metastasized and both metastasis subtypes combined from non-metastasized seminoma, respectively (Table 3). The overlap of small RNAs separating either lymphogen or occult metastasis from non-metastasized seminoma was 47-48% and increased up to 79% when comparing lymphogen and occult small RNAs candidates with the small RNAs based on the combined metastasis subtypes (Figure 1). We finally employed support vector machines which completely separated lymphogen, occult metastasis and the combined metastasis subtypes from non-metastasized seminoma using a combination of two small RNA species only (Table 4). Altogether, 891, 668 and 87 combinations allowed a complete separation of lymphogen (n = 5), occult metastasis (n = 5) and the combined metastasis subtypes (n = 10) from non-metastasized seminoma (n = 5), respectively.
Table 2

Descriptive statistics of number of reads before and after trimming and the percentage of annotated small RNAs measured in the peripheral blood of patients suffering from seminoma without metastasis as well as lymphogen and occult metastasized seminoma

Seminoma metastasis status

Total no. of reads

Reads after trimming

Annotated reads

Small RNA tags

abs.

%

abs.

%

abs.

abs. annotated

%

Non-metastasized, n = 5

       

Mean

1.3E + 07

9.7E + 06

76

8.1E + 06

84

2.2E + 05

1.6E + 04

7.2

Stdev

2.0E + 06

1.6E + 06

2.2

1.4E + 06

2.2

5.4E + 04

3.4E + 03

0.7

Min

9.4E + 06

7.1E + 06

72

5.7E + 06

81

1.7E + 05

1.2E + 04

6.5

Max

1.4E + 07

1.1E + 07

78

9.5E + 06

85

3.1E + 05

2.0E + 04

8.2

Lymphogen metastasized, n = 5

      

Mean

1.2E + 07

7.8E + 06

73

6.3E + 06

80

2.3E + 05

1.6E + 04

7.3

Stdev

6.5E + 06

3.1E + 06

16

2.7E + 06

3.8

8.6E + 04

3.2E + 03

1.5

Min

5.7E + 06

4.8E + 06

45

3.6E + 06

75

1.5E + 05

1.3E + 04

5.6

Max

2.0E + 07

1.2E + 07

86

1.0E + 07

85

3.3E + 05

1.9E + 04

8.5

Occult metastasized, n = 5

       

Mean

1.2E + 07

9.0E + 06

73

7.3E + 06

82

2.3E + 05

1.7E + 04

7.8

Stdev

4.3E + 06

3.5E + 06

6.6

2.8E + 06

2.5

5.1E + 04

9.4E + 02

1.4

Min

6.7E + 06

4.7E + 06

64

3.8E + 06

79

1.8E + 05

1.6E + 04

5.9

Max

1.9E + 07

1.4E + 07

81

1.1E + 07

85

3.1E + 05

1.8E + 04

10

Table 3

Summary of significantly associated small RNAs with metastasis status per group using logistic regression analysis (univariate)

Non versus metastasized (lymphogen and occult, n = 35)

Non versus lymphogen metastasized (n = 33)

Non versus occult metastasized (n = 34)

Small RNA

p-value

Fold-change

95% confidence interval

Small RNA

p-value

Fold-change

95% confidence interval

Small RNA

p-value

Fold-change

95% confidence interval

let-7f-1

0.04

5.5

1.3

23.7

let-7f-1

0.03

7.2

1.6

32.4

let-7a-1

0.02

3.1

1.4

7.0

mir-16-1

0.05

2.2

1.1

4.5

let-7f-2

0.04

8.1

1.5

44.6

let-7a-2

0.02

3.1

1.4

7.1

mir-18a

0.05

2.4

1.1

5.2

mir-15a

0.05

5.0

1.3

19.4

let-7a-3

0.02

3.1

1.4

7.0

mir-23a

0.05

2.7

1.1

6.5

mir-16-1

0.001

3.2

2.1

5.0

let-7b

0.01

3.1

1.6

6.1

mir-92a-1

0.008

2.7

1.4

5.1

mir-92a-1

0.007

3.0

1.6

5.5

let-7d

0.006

2.7

1.6

4.6

mir-92a-2

0.008

2.8

1.5

5.2

mir-92a-2

0.007

3.0

1.6

5.6

let-7f-1

0.006

3.8

1.9

7.6

mir-99a

0.01

2.5

1.3

4.6

mir-183

0.001

2.5

1.7

3.6

let-7f-2

0.01

3.8

1.7

8.3

mir-183

0.02

2.0

1.2

3.5

let-7 g

0.03

6.2

1.6

23.0

mir-18a

0.04

2.3

1.2

4.5

let-7 g

0.05

4.5

1.2

17.6

mir-15b

0.02

6.8

1.8

26.2

mir-92a-1

0.03

2.5

1.3

4.8

mir-23b

0.04

2.8

1.1

7.1

mir-23b

0.04

3.3

1.3

8.3

mir-92a-2

0.03

2.5

1.3

4.8

mir-130a

0.001

0.2

0.1

0.4

mir-130a

0.04

0.2

0.1

0.7

mir-99a

0.006

2.5

1.5

4.0

mir-191

0.004

0.4

0.2

0.7

mir-142

0.03

0.5

0.3

0.8

let-7 g

0.03

2.9

1.3

6.4

mir-296

0.01

2.3

1.3

4.0

mir-191

0.03

0.4

0.2

0.8

mir-30b

0.03

2.2

1.2

3.8

mir-378a

0.01

2.4

1.3

4.3

mir-126

0.03

2.0

1.2

3.4

mir-130a

0.03

0.1

0.0

0.5

mir-326

0.02

2.7

1.3

5.5

mir-296

0.01

2.2

1.4

3.6

mir-191

0.01

0.4

0.2

0.7

mir-331

0.01

3.0

1.4

6.3

mir-331

0.02

2.7

1.4

5.3

mir-29c

0.04

2.1

1.1

3.8

mir-339

0.04

2.1

1.1

4.0

mir-425

0.05

3.7

1.2

11.0

mir-296

0.04

2.4

1.2

4.7

mir-425

0.01

3.9

1.6

9.4

mir-451a

0.009

2.2

1.4

3.4

mir-378a

0.006

2.5

1.5

4.2

mir-451a

0.002

2.2

1.5

3.2

mir-92b

0.02

2.2

1.3

3.5

mir-326

0.01

3.4

1.7

6.9

mir-92b

0.02

2.5

1.2

5.0

mir-574

0.005

0.3

0.2

0.6

mir-331

0.03

3.3

1.4

7.9

mir-574

0.0001

0.4

0.2

0.5

mir-4286

0.04

3.3

1.3

8.7

mir-339

0.02

2.6

1.4

4.9

mir-4286

0.02

3.9

1.5

10.5

mir-4454

0.008

2.3

1.4

3.7

mir-425

0.002

4.1

2.2

7.5

mir-4454

0.03

2.7

1.2

5.9

ENST00000516594

0.007

0.4

0.2

0.6

mir-451a

0.01

2.2

1.4

3.5

ENST00000516594

0.02

0.5

0.3

0.8

ENST00000363271

0.007

0.4

0.2

0.6

mir-92b

0.04

2.8

1.2

6.4

ENST00000365160

0.03

0.4

0.2

0.8

ENST00000459091

0.002

0.3

0.2

0.5

mir-574

0.0009

0.4

0.3

0.6

ENST00000363271

0.02

0.5

0.3

0.8

ENST00000516350

0.007

0.4

0.2

0.6

mir-660

0.03

2.4

1.3

4.5

ENST00000459091

0.006

0.4

0.3

0.7

ENST00000517209

0.002

0.4

0.2

0.6

mir-664

0.02

2.1

1.3

3.5

ENST00000516350

0.02

0.5

0.3

0.8

ENST00000516507

0.007

0.4

0.2

0.7

mir-4286

0.02

4.5

1.7

11.8

ENST00000363865

0.02

0.5

0.3

0.8

ENST00000363865

0.007

0.4

0.2

0.6

mir-4454

0.05

3.0

1.2

7.5

ENST00000362808

0.02

0.5

0.3

0.8

ENST00000362808

0.007

0.4

0.2

0.6

ENST00000365160

0.04

0.3

0.1

0.8

ENST00000364409

0.02

0.5

0.3

0.8

ENST00000364409

0.007

0.4

0.2

0.6

ENST00000387347

0.01

3.1

1.6

6.0

ENST00000363745

0.02

0.5

0.3

0.8

ENST00000363745

0.007

0.4

0.2

0.6

ENST00000482884

0.05

2.6

1.2

5.6

ENST00000387347

0.03

3.0

1.3

7.3

ENST00000461337

0.007

0.4

0.2

0.6

ENST00000459949

0.002

2.3

1.6

3.4

ENST00000459949

0.003

2.0

1.4

2.9

     

ENST00000410361

0.02

3.3

1.4

7.8

ENST00000461337

0.02

0.5

0.3

0.8

          
Figure 1

Venn diagram showing the total number (bold) and overlapping number of significantly associated small RNAs (from Table 3 ) to discriminate different metastasis subtypes (lymphogen, occult and the combination of both subtypes) from non-metastasized seminoma.

Table 4

Summary on combinations of two small RNAs (small RNA1 with small RNA2) which together completely discriminate metastasis subtypes (lymphogen, occult and their combination) from non-metastasized seminoma employing support vector machines

Non versus metastasized (lymphogen and occult, n = 87)

Non versus lymphogen metastasized (n = 87 from 891)

Non versus occult metastasized (=87 from 668)

Small RNA1

Small RNA2

Small RNA1

Small RNA2

Small RNA1

Small RNA2

let-7f-1

mir-191

let-7a-1

mir-192

let-7a-1

mir-223

let-7f-1

mir-574

let-7a-1

mir-191

let-7a-1

mir-574

let-7f-2

mir-191

let-7a-1

mir-532

let-7a-1

mir-4454

mir-18a

mir-532

let-7a-1

ENST00000516594

let-7a-2

mir-223

mir-19b-1

mir-342

let-7a-1

ENST00000363271

let-7a-2

mir-574

mir-19b-1

ENST00000517209

let-7a-1

ENST00000459091

let-7a-2

mir-4454

mir-19b-2

mir-342

let-7a-1

ENST00000516350

let-7a-3

mir-223

mir-19b-2

ENST00000517209

let-7a-1

ENST00000517209

let-7a-3

mir-574

mir-28

mir-574

let-7a-1

ENST00000516501

let-7a-3

mir-4454

mir-29a

mir-223

let-7a-1

ENST00000516507

let-7b

mir-16-1

mir-29a

mir-574

let-7a-1

ENST00000363865

let-7b

mir-19b-1

mir-93

mir-532

let-7a-1

ENST00000362808

let-7b

mir-19b-2

mir-99a

mir-574

let-7a-1

ENST00000364409

let-7b

mir-22

mir-192

ENST00000459091

let-7a-1

ENST00000363745

let-7b

mir-23a

mir-197

mir-92b

let-7a-1

ENST00000461337

let-7b

mir-24-1

mir-197

mir-4454

let-7a-2

mir-192

let-7b

mir-24-2

mir-183

mir-191

let-7a-2

mir-191

let-7b

mir-25

mir-223

mir-145

let-7a-2

mir-532

let-7b

mir-26a-1

mir-223

mir-423

let-7a-2

ENST00000516594

let-7b

mir-26b

mir-223

mir-664

let-7a-2

ENST00000363271

let-7b

mir-28

mir-223

ENST00000459091

let-7a-2

ENST00000459091

let-7b

mir-29a

mir-30b

mir-574

let-7a-2

ENST00000516350

let-7b

mir-29b-1

mir-125b-1

mir-130a

let-7a-2

ENST00000517209

let-7b

mir-29b-2

mir-130a

mir-142

let-7a-2

ENST00000516501

let-7b

mir-103a-2

mir-130a

mir-125b-2

let-7a-2

ENST00000516507

let-7b

mir-103a-1

mir-130a

mir-150

let-7a-2

ENST00000363865

let-7b

mir-107

mir-130a

mir-186

let-7a-2

ENST00000362808

let-7b

mir-16-2

mir-130a

mir-361

let-7a-2

ENST00000364409

let-7b

mir-192

mir-130a

mir-340

let-7a-2

ENST00000363745

let-7b

mir-197

mir-130a

mir-342

let-7a-2

ENST00000461337

let-7b

mir-181a-2

mir-130a

mir-574

let-7a-3

mir-192

let-7b

mir-182

mir-140

mir-342

let-7a-3

mir-191

let-7b

mir-181a-1

mir-140

mir-532

let-7a-3

mir-532

let-7b

mir-221

mir-142

mir-326

let-7a-3

ENST00000516594

let-7b

mir-223

mir-142

mir-423

let-7a-3

ENST00000363271

let-7b

mir-23b

mir-142

mir-425

let-7a-3

ENST00000459091

let-7b

mir-125b-1

mir-142

mir-451a

let-7a-3

ENST00000516350

let-7b

mir-130a

mir-191

mir-92b

let-7a-3

ENST00000517209

let-7b

mir-140

mir-29c

mir-342

let-7a-3

ENST00000516501

let-7b

mir-142

mir-29c

mir-574

let-7a-3

ENST00000516507

let-7b

mir-191

mir-378a

mir-532

let-7a-3

ENST00000363865

let-7b

mir-125a

mir-378a

mir-574

let-7a-3

ENST00000362808

let-7b

mir-125b-2

mir-342

mir-423

let-7a-3

ENST00000364409

let-7b

mir-126

mir-342

mir-425

let-7a-3

ENST00000363745

let-7b

mir-186

mir-342

mir-3676

let-7a-3

ENST00000461337

let-7b

mir-320a

mir-342

ENST00000387347

let-7b

mir-192

let-7b

mir-106b

mir-342

ENST00000482884

let-7b

mir-191

let-7b

mir-29c

mir-326

mir-532

let-7b

mir-532

let-7b

mir-296

mir-326

mir-574

let-7b

ENST00000516594

let-7b

mir-26a-2

mir-326

ENST00000517209

let-7b

ENST00000363271

let-7b

mir-361

mir-423

mir-574

let-7b

ENST00000459091

let-7b

mir-378a

mir-425

mir-532

let-7b

ENST00000516350

let-7b

mir-340

mir-425

mir-629

let-7b

ENST00000517209

let-7b

mir-328

mir-425

ENST00000517209

let-7b

ENST00000516501

let-7b

mir-342

mir-451a

mir-574

let-7b

ENST00000516507

let-7b

mir-326

mir-484

mir-574

let-7b

ENST00000363865

let-7b

mir-151a

mir-532

mir-92b

let-7b

ENST00000362808

let-7b

mir-331

mir-532

mir-625

let-7b

ENST00000364409

let-7b

mir-324

mir-532

mir-660

let-7b

ENST00000363745

let-7b

mir-339

mir-532

ENST00000482884

let-7b

ENST00000461337

let-7b

mir-345

mir-92b

mir-574

let-7d

mir-192

let-7b

mir-423

mir-574

mir-625

let-7d

mir-191

let-7b

mir-425

mir-574

mir-454

let-7d

mir-532

let-7b

mir-451a

mir-574

mir-664

let-7d

ENST00000516594

let-7b

mir-484

mir-574

mir-4454

let-7d

ENST00000363271

let-7b

mir-505

mir-574

ENST00000516594

let-7d

ENST00000459091

let-7b

mir-532

mir-574

ENST00000363271

let-7d

ENST00000516350

let-7b

mir-574

mir-574

ENST00000459091

let-7d

ENST00000517209

let-7b

mir-652

mir-574

ENST00000516350

let-7d

ENST00000516501

let-7b

mir-766

mir-574

ENST00000516507

let-7d

ENST00000516507

let-7b

mir-744

mir-574

ENST00000363865

let-7d

ENST00000363865

let-7b

mir-1260a

mir-574

ENST00000362808

let-7d

ENST00000362808

let-7b

mir-1280

mir-574

ENST00000364409

let-7d

ENST00000364409

let-7b

mir-1260b

mir-574

ENST00000363745

let-7d

ENST00000363745

let-7b

mir-4286

mir-574

ENST00000387347

let-7d

ENST00000461337

let-7b

mir-3676

mir-574

ENST00000459949

let-7f-1

mir-192

let-7b

mir-4454

mir-574

ENST00000461337

let-7f-1

mir-191

let-7b

ENST00000516572

mir-1260a

ENST00000459091

let-7f-1

mir-532

let-7b

ENST00000516351

mir-3676

ENST00000517209

let-7f-1

ENST00000516594

let-7b

ENST00000516461

mir-4454

ENST00000459091

let-7f-1

ENST00000363271

let-7b

ENST00000516775

mir-4454

ENST00000466665

let-7f-1

ENST00000459091

let-7b

ENST00000516594

ENST00000516572

ENST00000459091

let-7f-1

ENST00000516350

let-7b

ENST00000365160

ENST00000516351

ENST00000459091

let-7f-1

ENST00000517209

let-7b

ENST00000363271

ENST00000459091

ENST00000463508

let-7f-1

ENST00000516501

let-7b

ENST00000459091

ENST00000459091

ENST00000482884

let-7f-1

ENST00000516507

let-7b

ENST00000516350

ENST00000459091

ENST00000488123

let-7f-1

ENST00000363865

let-7b

ENST00000517209

ENST00000517209

ENST00000482884

let-7f-1

ENST00000362808

let-7b

ENST00000516501

From the total number of small RNA combinations per group (shown in parenthesis) only 87 combinations per group are presented.

Discussion

In our study we aimed to better discriminate metastasized (either lymphogen or occult subtypes or both combined) from non-metastasized seminoma based on small RNA changes examined in the peripheral blood. A whole genome screening on small RNA species was performed employing NGS. We demonstrated each metastasis subtype and its combination to be completely discriminated from non-metastasized seminoma using two small RNAs combined.

MicroRNAs are previously described to be involved in different distant (e.g. migration, angiogenesis and colonization of distant organs) and local (e.g. changes in tumor microenvironment) processes in metastatic cascade. Interestingly, the microRNAs identified in our study are involved in local tumour microenvironmental changes only. For instance, members of the Let-7 family are involved in inflammatory processes as a part of the metastatic cascade. The Let-7 family targets oncogenes such as HMGA2 and KRAS and seem to be a key component in a so called epigenetic switch [1315]. Cancer associated fibroblasts are involved in tumor formation and progression where miR-15 and miR-16 regulate FGF2 and FGFR1 in prostate cancer [16] and miR-18 in breast cancer [17].

Recently other authors demonstrated that microRNA 371-73 cluster and microRNA 302 discriminated seminoma bearing patients from healthy persons [68]. We did the next step and examined the suitability of these microRNA to predict the metastasis status, these microRNA 371-73 cluster and miRNA 302 was detectable in our analysis, but appeared not significantly associated with the metastasis status as it is true for protein tumour markers (e.g. HCG) as well.

The complete separation of metastasis from non-metastasized seminoma using a combination of two small RNA species points to the significant diagnostic potential of these biological marker which is in line with previous examinations on the transcriptional level showing the superiority of molecular marker over epidemiological or clinical-histological parameter [18, 19]. After validation of these results on a larger group, these findings could help for therapy decision making in favour of adjuvant chemotherapy or surveillance based on miRNA expression changes predicting metastasis spread, even if metastasis spreads are not visible using a CT scan.

Interesting, the discrimination in our study occurred irrespective of the metastasis subtype and with the same microRNAs in up to 79%. This was expected, since we recently demonstrated lymphogen and occult metastasized seminoma to be indistinguishable on the transcriptional and post-transcriptional level (revised version submitted).

Noteworthy, these changes were examined in the peripheral blood of seminoma patients taken at the time of the primary tumour’s diagnosis. It can be hypothesized that our measurements are linked to seminoma tumour cells circulating in the peripheral blood.

Our study has certain weaknesses such as the low number of cases examined (total n = 15). However, the molecular biological methodology applied provides a deepness, which under financial considerations does not allow large scale studies. Hence, this study provides hints towards certain small RNA species comprising a significant diagnostic potential for prediction of seminoma metastasis based on examinations in the peripheral blood, but certainly these candidate small RNA species have to be examined on a larger independent group for validation purposes. The validation should also include haematogenous metastasized seminoma (clinical Stage III), not included in this study, to prove the usability in this tumor stage as well. Furthermore, we did not adjust the p-values for multiple comparisons, because of the explorative character of this study and the low sample size. Based on experiences with previous work we expect about 10-20% of our candidates being false positives/negatives [20]. However, this study represents a screening approach. About 100 most promising candidate genes will be considered for validation in a following study using another group and another methodology (qRT-PCR).

Conclusion

Metastasized (either lymphogen or occult) seminoma can be completely discriminated from non-metastasized seminoma with a combination of two small RNAs measured in the peripheral blood.

Methods

Patient selection

Non-metastasized seminoma (n = 5) received no adjuvant treatment and were free of relapse/progress for at least two years of follow up. Occult metastasized patients (n = 5) presented without visible metastasis at primary staging, received no adjuvant treatment, and developed retroperitoneal tumour progress during the follow up of 12 month. For patients with detectable metastasis at primary staging (n = 5) we focused on clinical stage IIb and IIc, to include lymphogenic metastatic spread only and to provide a high level of diagnostic accuracy (avoiding doubtful lymph nodes). Lymphogen metastasis and non-metastasized patients were matched with occult metastasized patients considering demographic and histological parameters where applicable as well as quality criteria for isolated RNA (Table 1). All patients included in this study were treated between 2008 and 2010 in one testis cancer centre. These 15 patients were selected out of about 300 seminoma patients, according to the criteria mentioned above.

Histological examination

All testicular tumours (n = 15) were examined by an experienced pathologist for histological and TNM classification (Table 1) and pure seminoma was diagnosed in all cases.

Blood sample taking

Whole blood samples (2.5 ml) were taken intraoperative from cubital vein directly into the PAXgene Blood RNA system (BD Diagnostics, PreAnalytiX GmbH, Hombrechtikon, Switzerland). The tube was gently inverted (10 times), settled at room temperature overnight and stored at -20° until use. The Ethical Review Committee of the Medical Association Hamburg approved the study and all human samples were obtained with written informed consent.

RNA Isolation

After thawing the PAXGene tubes, and washing and centrifugation of the samples the cells became lysed (Proteinase K) followed by adding Lysis/Binding Solution taken from the mirVana Kit (Life Technologies, Darmstadt, Germany). With the mirVana kit total RNA including small RNA species was isolated by combining a Phenol-Chloroform RNA precipitation with further processing using a silica membrane. After several washing procedures DNA residuals became digested on the membrane (RNAse free DNAse Set, Qiagen, Hilden, Germany), washed, RNA was eluted in a collection tube and frozen at -80°C. Quality and quantity of isolated total RNA were measured spectrophotometrically (NanoDrop, PeqLab Biotechnology, Erlangen, Germany). RNA integrity was assessed by the 2100 Agilent Bioanalyser (Life Science Group, Penzberg, Germany) and DNA contamination was controlled by conventional PCR using actin primer.

For analysis, we used only RNA specimens with a ratio of A260/A280 ≥ 2.0 (Nanodrop) and RNA integrity number (RIN) between 6.0-9.3 for small RNA Next Generation Sequencing (IMGM Laboratories, Martinsried, Germany/CeGat, Tübingen, Germany). For RNA samples with RIN below 7.0 or questionable 28/18S bands (indications of RNA degradation) we performed additional checks to exclude the presence of RNAses and true RNA-degradation.

Small RNA next generation sequencing and data analysis

We performed a genome wide small RNA sequencing using the SOLiD5500xl Next Generation Sequencing Technology (Life Technologies, Penzberg, Germany). In brief, total RNA was purified (PureLink microRNA isolation Kit), enriched small RNAs were ligated to SOLiD adaptors, reverse transcribed (SOLiD RT primer and ArrayScript RT), cDNA was purified (MinElute PCR purification Kit, Qiagen), a cut-off size of 60-80 nt was selected (Novex pre-cast gel products, invitrogen), cDNA was in-gel amplified and samples were barcoded using SOLiD 3′Barcode primer at the same time. Amplified cDNA was purified (PureLink PCR Micro Kit, Life Technologies) and used in emulsion PCR (SOLiD EZ Bead). Thereafter, the emulsion was broken to recover enriched beads and the so-called di-base probes were used by the SOLiD system in the sequencing-by-ligation procedure. Beside the SOLiD5500xl inherent software (LifeScope) used for image and signal processing, software CLC Genomics Workbench 5.1 (CLC bio) was used for clustering, counting, and annotation of all generated 75 bp reads. After discarding reads without adaptor sequence and being shorter than 15 bp (trimming) reads were assigned to known microRNAs (Sanger miRBase release 18, http://www.mirbase.org/) and known non-coding RNAs (ensembl database Homo_sapiens.GRCh37.67.ncrna.fa, http://www.ensembl.org). Small RNAs showing a significant and ≥ 2-fold differences in gene expression among groups and at least 50 reads were further analysed on their ability to separate both groups using univariate logistic regression analysis [21] and combinations of two small RNAs were examined employing support vector machines (linear Kermel).

Abbreviations

bp: 

Base pair

cDNA: 

Copy deoxyribonucleic acids

cS: 

clincal stage

CT scan: 

Computed tomography

DNA: 

Deoxyribonucleic acids

miRNA: 

micro ribonucleic acid

NGS: 

Next generation sequencing

qRT-PCR: 

Quantitative real time polymerase chain reaction

RNA: 

Ribonucleic acid

RIN: 

RNA integrity number

TNM-Classicfication: 

Tumor nodus metastasis classification.

Declarations

Acknowledgements

We would like to thank S. Senf for his skilful technical assistance. The German Ministry of Defence supported this work.

Authors’ Affiliations

(1)
Department of Urology, Federal Armed Forces Hospital
(2)
Bundeswehr Institute of Radiobiology
(3)
Department of Urology, Federal Armed Forces Central Hospital
(4)
Department of Hematology, Hemostasis Oncology and Stem Cell Transplantation, MHH
(5)
Max Planck Institute of Psychiatry

References

  1. Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP: Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing(). Urol Oncol. 2014, 32 (1): 33-e1-6. doi:10.1016/j.urolonc.2012.12.002. Epub 2013 Feb 6View ArticlePubMedGoogle Scholar
  2. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008, 53: 478-496. 10.1016/j.eururo.2007.12.024View ArticlePubMedGoogle Scholar
  3. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP: [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp. 2012, 36: 127-145.View ArticlePubMedGoogle Scholar
  4. Ruf CG, Khalili-Harbi N, Sachs S, Isbarn H, Wagner W, Matthies C, Meineke V, Fisch M, Chun FK, Abend M: The search for biomarkers of metastatic seminoma. J Urol. 2013, 190 (3): 1046-1051. doi:10.1016/j.juro.2013.04.022. Epub 2013 Apr 10View ArticlePubMedGoogle Scholar
  5. Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, Black P, Duncan G, Hayes-Lattin B, Nichols C: Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011, 22: 808-814. 10.1093/annonc/mdq466View ArticlePubMedGoogle Scholar
  6. Dieckmann KP, Spiekermann M, Balks T, Flor I, Loning T, Bullerdiek J, Belge G: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 2012, 107: 1754-1760. 10.1038/bjc.2012.469PubMed CentralView ArticlePubMedGoogle Scholar
  7. Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, Chen C, Guenther S, Sherlock J, Veltman I, Baeten J, van der Spek PJ, de Alarcon P, Looijenga LH: High-throughput microRNAome analysis in human germ cell tumours. J Pathol. 2007, 213: 319-328. 10.1002/path.2230View ArticlePubMedGoogle Scholar
  8. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, Pett MR, Thornton CM, Nicholson JC, Enright AJ, Coleman N, : Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 2010, 70: 2911-2923. 10.1158/0008-5472.CAN-09-3301PubMed CentralView ArticlePubMedGoogle Scholar
  9. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M: Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer. 2011, 10: 52- 10.1186/1476-4598-10-52PubMed CentralView ArticlePubMedGoogle Scholar
  10. Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, Zhou X: MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 2009, 6: 131-139.PubMed CentralPubMedGoogle Scholar
  11. Profumo V, Gandellini P: MicroRNAs: cobblestones on the road to cancer metastasis. Crit Rev Oncog. 2013, 18: 341-355. 10.1615/CritRevOncog.2013007182View ArticlePubMedGoogle Scholar
  12. Ruf CG, Nastaly P, Becker P, Isbarn H, Honecker F, Pantel K, Riethdorf S, Hoeppner D, Fisch M, Wagner W, Ahyai S: Circulating tumor cells can be detected in patients with testicular germ cell tumors. J Urol. 2013, 189: e289-View ArticleGoogle Scholar
  13. Mayr C, Hemann MT, Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007, 315: 1576-1579. 10.1126/science.1137999PubMed CentralView ArticlePubMedGoogle Scholar
  14. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 2005, 120: 635-647. 10.1016/j.cell.2005.01.014View ArticlePubMedGoogle Scholar
  15. Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009, 139: 693-706. 10.1016/j.cell.2009.10.014PubMed CentralView ArticlePubMedGoogle Scholar
  16. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D'Urso L, Falchi M, Venneri MA, Muto G, De Maria R, Bonci D: Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011, 30: 4231-4242. 10.1038/onc.2011.140View ArticlePubMedGoogle Scholar
  17. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG: microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A. 2010, 107: 8231-8236. 10.1073/pnas.1002080107PubMed CentralView ArticlePubMedGoogle Scholar
  18. Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M: Predicting metastasized seminoma using gene expression. BJU Int. 2012, 110: E14-E20. 10.1111/j.1464-410X.2011.10778.xView ArticlePubMedGoogle Scholar
  19. Port M, Wang Y, Schmelz HU, Pottek T, Meineke V, Ruf C, Abend M: A gene signature of primary tumor identifies metastasized seminoma. Urol Oncol. 2011, 29: 764-773. 10.1016/j.urolonc.2009.08.008View ArticlePubMedGoogle Scholar
  20. Port M, Seidl C, Ruf CG, Riecke A, Meineke V, Abend M: Reliable and sample saving gene expression analysis approach for diagnostic tool development. Health Phys. 2012, 103: 159-168.PubMedGoogle Scholar
  21. Baggerly KA, Deng L, Morris JS, Aldaz CM: Overdispersed logistic regression for SAGE: modelling multiple groups and covariates. BMC Bioinform. 2004, 5: 144-10.1186/1471-2105-5-144.View ArticleGoogle Scholar

Copyright

© Ruf et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement